Scientific Advisory Board

B-MoGen utilizes the breadth and depth of experience with leaders in genome engineering to shape and guide our products and portfolio development.

Dr. Perry Hacket Ph.D. B-MoGen

Perry Hacket, Ph.D.

The Hackett lab’s main area of interest is using transposons as vectors for gene therapy as well as tagging and mapping genes in vertebrate chromosomes. For this, we use the Sleeping Beauty Transposon System, a system we created from extinct transposons that had been asleep for more than 10 million years. The lab works very closely with other labs in the Center for Genome Engineering including the McIvor, Largaespada, Somia and Voytas labs.

Dr. Robert “Bob” Preti Ph.D. B-MoGen

Robert “Bob” Preti, Ph.D.

Robert “Bob” Preti is Progenitor Cell Therapy’s (PCT) co-founder and the visionary behind its successful growth over the last two decades. Bob built PCT to meet a recognized need for high quality manufacturing and development services in the Cellular Therapy sector. PCT has now served over 100 Clients and performed more than 20,000 cell therapy procedures. His leadership has been instrumental in creating PCT’s Client-focused model that helps bridge the gap between discovery and patient care. Before assuming his role at PCT, Bob held a number of positions within the cellular therapy and blood banking fields. From 1996 to 1999, he was the director of hematopoietic stem cell processing and applied research at Hackensack University Medical Center. He served in several capacities with the New York Blood Center from 1990 to 1997. He also worked as a research scientist for Marrow-Tech Incorporated, which went on to become Advanced Tissue Sciences (ATIS), where work in his laboratory lead to the Dermagraft product currently marketed by Organogenesis.

Dr. David McKenna, M.D.

David McKenna, M.D.

Dr. McKenna is a Professor of Laboratory Medicine & Pathology at the University of Minnesota where he holds the American Red Cross Chair in Transfusion Medicine. He serves as the Scientific and Medical Director of Molecular and Cellular Therapeutics (MCT), the University’s cGMP facility, the Director of the Division of Transfusion Medicine, and the Program Director of the Transfusion Medicine Fellowship. He is a leader in the field of cellular therapy, serving on several committees and boards for NIH, FDA, and professional organizations such as aabb. He is the PI or co-I on several grants and contracts related to cellular therapies with NIH and DoD.

David A. Largaespada, Ph.D. B-MoGen

David A. Largaespada, Ph.D.

Chairman, Scientific Advisory Board

Dr. Largaespada is an authority on mouse genetics, gene modification, cancer genes, and disease models. His outstanding background was integral to the founding of B-MoGen Biotechnologies, Inc. He spent five years as a postdoctoral fellow in Frederick, Maryland at the National Cancer Institute working with world-renowned geneticists Dr. Nancy Jenkins and Dr. Neal Copeland, where the Leukemia and Lymphoma Society of America awarded him a postdoctoral fellowship. He is currently a Full Professor in the Department of Pediatrics and the Department of Genetics, Cell Biology and Development at the University of Minnesota.

Branden S. Moriarity, Ph.D. B-MoGen

Branden S. Moriarity, Ph.D.

Chief Scientific Officer

Dr. Moriarity is an expert in genome engineering using both cut and paste DNA transposon systems, such as Sleeping Beauty and piggyBac, and both TALEN and CRISPR targeted nuclease platforms. These technologies are at the core of B-MoGen Biotechnologies, Inc. He spent five years as a graduate student and 2 years as a postdoctoral fellow at the University of Minnesota working with Dr. David A. Largaespada, an authority on mouse genetics, gene modification, cancer genes, and disease models. He was ‘fast tracked’ to the position of Assistant Professor in the Department of Pediatrics at the University of Minnesota in 2014.

Beau R. Webber, Ph.D. B-MoGen

Beau R. Webber, Ph.D.

Chief Technology Officer

Dr. Webber is an expert in the areas of stem cell biology, hematology and immunology, and genetic engineering. He has extensive experience in the genetic modification of both human and mouse cell lines, primary cell types including lymphocytes and hematopoietic stem cells, and pluripotent cells including embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC) using targeted nucleases such as TALEN and CRISPR/Cas9, as well as cut and paste transposon systems such as Sleeping Beauty and piggyBAC. Dr. Webber graduated summa cum laude from the University of Wisconsin with a B.S. in Cellular and Molecular Biology and was voted by faculty as Outstanding Senior of the Year in the Cellular and Molecular Biology program. He conducted his PhD studies at the University of Minnesota as a fellow in the Stem Cell Institute training program under the mentorship of Drs. Bruce Blazar and Jakub Tolar. As a postdoctoral fellow in the Hematology, Oncology, and Transplantation program, Dr. Webber developed advanced strategies for genetic modification of primary human lymphohematopoietic and pluripotent stem cells for cancer immunotherapy and correction of inherited diseases. Dr. Webber has published numerous peer-reviewed articles in the areas of stem cell biology, hematology, and genome engineering and is currently an Assistant Professor in the Department of Pediatrics, Division of Hematology and Oncology at the University of Minnesota.